110 related articles for article (PubMed ID: 32617785)
1. Antiproliferative effect of bacterial cyclodipeptides in the HeLa line of human cervical cancer reveals multiple protein kinase targeting, including mTORC1/C2 complex inhibition in a TSC1/2-dependent manner.
Hernández-Padilla L; Reyes de la Cruz H; Campos-García J
Apoptosis; 2020 Oct; 25(9-10):632-647. PubMed ID: 32617785
[TBL] [Abstract][Full Text] [Related]
2. Bacterial Cyclodipeptides Target Signal Pathways Involved in Malignant Melanoma.
Durán-Maldonado MX; Hernández-Padilla L; Gallardo-Pérez JC; Díaz-Pérez AL; Martínez-Alcantar L; Reyes De la Cruz H; Rodríguez-Zavala JS; Pacheco-Rodríguez G; Moss J; Campos-García J
Front Oncol; 2020; 10():1111. PubMed ID: 32793477
[TBL] [Abstract][Full Text] [Related]
3. The Antiproliferative Effect of Cyclodipeptides from Pseudomonas aeruginosa PAO1 on HeLa Cells Involves Inhibition of Phosphorylation of Akt and S6k Kinases.
Hernández-Padilla L; Vázquez-Rivera D; Sánchez-Briones LA; Díaz-Pérez AL; Moreno-Rodríguez J; Moreno-Eutimio MA; Meza-Carmen V; Cruz HR; Campos-García J
Molecules; 2017 Jun; 22(6):. PubMed ID: 28632179
[No Abstract] [Full Text] [Related]
4. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
5. The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells.
Hernández-Padilla L; Durán-Maldonado MX; Martínez-Alcantar L; Rodríguez-Zavala JS; Campos-Garcia J
Curr Cancer Drug Targets; 2024 Apr; ():. PubMed ID: 38629372
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomics Reveals the Mevalonate and Cholesterol Pathways Blocking as Part of the Bacterial Cyclodipeptides Cytotoxic Effects in HeLa Cells of Human Cervix Adenocarcinoma.
Lázaro-Mixteco PE; González-Coronel JM; Hernández-Padilla L; Martínez-Alcantar L; Martínez-Carranza E; López-Bucio JS; Guevara-García ÁA; Campos-García J
Front Oncol; 2022; 12():790537. PubMed ID: 35359411
[TBL] [Abstract][Full Text] [Related]
7. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
[TBL] [Abstract][Full Text] [Related]
8. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
9. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
10. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
11. CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia.
Chiang YJ; Liao WT; Ho KC; Wang SH; Chen YG; Ho CL; Huang SF; Shih LY; Yang-Yen HF; Yen JJ
Oncogene; 2019 Feb; 38(9):1432-1447. PubMed ID: 30266989
[TBL] [Abstract][Full Text] [Related]
12. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
13. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells.
Chen W; Pan Y; Wang S; Liu Y; Chen G; Zhou L; Ni W; Wang A; Lu Y
BMC Cancer; 2017 Jan; 17(1):34. PubMed ID: 28061838
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of TSC2 by PKC-δ reveals a novel signaling pathway that couples protein synthesis to mTORC1 activity.
Zhan J; Chitta RK; Harwood FC; Grosveld GC
Mol Cell Biochem; 2019 Jun; 456(1-2):123-134. PubMed ID: 30684133
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
[TBL] [Abstract][Full Text] [Related]
16. Tuberous sclerosis complex is required for tumor maintenance in MYC-driven Burkitt's lymphoma.
Hartleben G; Müller C; Krämer A; Schimmel H; Zidek LM; Dornblut C; Winkler R; Eichwald S; Kortman G; Kosan C; Kluiver J; Petersen I; van den Berg A; Wang ZQ; Calkhoven CF
EMBO J; 2018 Nov; 37(21):. PubMed ID: 30237309
[TBL] [Abstract][Full Text] [Related]
17. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
18. Regulation of mTORC1 signaling by pH.
Balgi AD; Diering GH; Donohue E; Lam KK; Fonseca BD; Zimmerman C; Numata M; Roberge M
PLoS One; 2011; 6(6):e21549. PubMed ID: 21738705
[TBL] [Abstract][Full Text] [Related]
19. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
20. A new homozygous HERC1 gain-of-function variant in MDFPMR syndrome leads to mTORC1 hyperactivation and reduced autophagy during cell catabolism.
Schwarz JM; Pedrazza L; Stenzel W; Rosa JL; Schuelke M; Straussberg R
Mol Genet Metab; 2020; 131(1-2):126-134. PubMed ID: 32921582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
